, Xian-Feng Wen 1 & Xiangwei Wu 1, 4 Cancer chemoprevention uses natural, synthetic, or biological substances to reverse, suppress, or prevent either the initial phase of carcinogenesis or the progression of neoplastic cells to cancer 1 . It holds promise for overcoming problems associated with the treatment of late-stage cancers. However, the broad application of chemoprevention is compromised at present by limited effectiveness and potential toxicity. To overcome these challenges, here we developed a new chemoprevention approach that specifically targets premalignant tumour cells for apoptosis. We show that a deficiency in the adenomatous polyposis coli (APC) gene and subsequent activation of b-catenin lead to the repression of cellular caspase-8 inhibitor c-FLIP (also known as CFLAR) expression through activation of c-Myc, and that all-trans-retinyl acetate (RAc) independently upregulates tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptors and suppresses decoy receptors. Thus, the combination of TRAIL and RAc induces apoptosis in APC-deficient premalignant cells without affecting normal cells in vitro. In addition, we show that shortterm and non-continuous TRAIL and RAc treatment induce apoptosis specifically in intestinal polyps, strongly inhibit tumour growth, and prolong survival in multiple intestinal neoplasms C57BL/6J-Apc Min /J (Apc Min ) mice. With our approach, we further demonstrate that TRAIL and RAc induce significant cell death in human colon polyps, providing a potentially selective approach for colorectal cancer chemoprevention by targeting APC-deficient cells for apoptosis.
TRAIL (also known as TNFSF10 or Apo2L), is a membrane-bound TNF family ligand 2, 3 . Although TRAIL induces apoptosis in cancer cells, it does not harm normal cells 4, 5 . To test the response of premalignant tumour cells to TRAIL, we isolated primary adenoma cells from intestinal polyps (benign adenomas) of Apc Min mice [6] [7] [8] . We also isolated intestinal epithelial cells from wild-type mice as controls (Supplementary Fig. 1a) . TRAIL treatment did not induce any apoptosis in the isolated epithelial cells (Fig. 1a and Supplementary Fig. 1b ). Previous reports indicate that certain retinoids synergize TRAIL-induced apoptosis in some cancer cell lines by inducing either TRAIL or its death receptors [9] [10] [11] . We explored the effect of RAc on TRAIL sensitivity in isolated primary adenoma and normal epithelial cells. Although RAc alone had no effect on the survival of either normal cells from control mice or adenoma cells, it specifically sensitized the adenoma cells to TRAIL-induced cell death ( Fig. 1a and Supplementary Fig. 1b) . These results show that RAc and TRAIL synergistically induce apoptosis in intestinal adenoma cells derived from Apc Min mice. The major difference between adenoma cells and normal cells is the loss of the wild-type APC allele in adenoma cells 12 . To test the role of APC in cell sensitivity to TRAIL and RAc, we knocked down APC expression in an immortalized normal human colon epithelial cell line, NCM356, using APC small interfering RNA (APC-siRNA) (Fig. 1b) . We observed that APC knockdown and treatment with TRAIL and RAc resulted in caspase 8 cleavage and an increase in caspase 3/7 activity ( Fig. 1c and Supplementary Fig. 1c ). Furthermore, the caspase 8 inhibitor Z-IETD blocked caspase 3/7 activity ( Supplementary  Fig. 1c ), suggesting that caspase 8 processing resulted in its activation. Similar results were obtained using an immortalized normal human bronchial epithelial cell line (BEAS-2B-BW1799 or BW1799) (Supplementary Fig. 2 ). These results demonstrate that APC deficiency is a, Primary epithelial cells were isolated from normal mouse intestine and polyps from Apc Min mice, and treated with TRAIL (50 ng ml 21 for 24 h), RAc (6.8 ng ml 21 for 48 h), or both (RAc for 48 h then TRAIL for 24 h). Cells were stained with annexin V-FITC (fluorescein isothiocyanate) and propidium iodide (PI). Early apoptotic cells (annexin V-positive, PI-negative) were counted. The data represent results from three independent experiments. Mean and s.d. are shown. b, Immortalized normal human colon epithelial cells (NCM356) were transfected with either non-specific (NS)-siRNA or APC-siRNA, and APC protein was detected 48 h after transfection by western blotting. c, The transfected NCM356 cells were treated and collected, and both full-length pro-caspase 8 and cleaved forms (p44/42 and p18) were detected by western blotting.
the key factor in sensitizing normal cells to apoptosis induced by the combination of TRAIL and RAc.
Inactivation of APC leads to stabilization and nuclear translocation of b-catenin, and to transcriptional activation of target genes, such as c-Myc (also known as MYC) and cyclin D1 (CCDN1) 13 . To investigate the signalling events in the APC pathway required for sensitizing cells to TRAIL and RAc, we transfected either stabilized b-catenin 14 or full-length c-Myc into NCM356 cells ( Supplementary  Fig. 3a, b) . The expression of either b-catenin mutant or c-Myc led to TRAIL-and RAc-mediated caspase 8 cleavage and activation ( Fig. 2a and Supplementary Fig. 3c ). Transfection of cyclin D1 had no effect on TRAIL-and RAc-induced apoptosis in NCM356 and other cells (data not shown). We then determined the requirement of c-Myc for sensitizing cells to TRAIL and RAc. APC knockdown led to an increase in c-Myc expression, as expected. Co-transfection of c-Myc-siRNA blocked APC deficiency-mediated c-Myc induction and caspase 8 cleavage/activation in response to TRAIL and RAc ( Fig. 2b and Supplementary Fig. 3c ). We further confirmed these observations using independent siRNAs ( Supplementary Fig. 4 ). These results indicate that the effect of APC on the cell response to TRAIL and RAc is largely dependent on APC/b-catenin-mediated activation of c-Myc.
Other studies have shown that c-Myc directly suppresses c-FLIP expression, and that this activity correlates with TRAIL sensitivity 15 . NCM356 cells expressed readily detectable c-FLIP, and transfection of c-Myc resulted in a significant decrease in c-FLIP expression and caspase 8 cleavage ( 5 ). In addition to suppressing c-FLIP expression, c-Myc could also act on mitochondria to facilitate TRAIL-induced apoptosis 16 . To test this possibility, we performed rescue experiments using BCL2 and BCL-XL (also known as BCL2L1). Overexpression of either BCL2 or BCL-XL did not inhibit c-Myc-mediated caspase 8 processing and activation in response to TRAIL and RAc ( Fig. 2c and Supplementary Fig. 3c ). These results indicate that APC deficiency sensitizes normal cells to TRAIL and RAc by suppressing c-FLIP expression through the activation of b-catenin and c-Myc.
Previous reports have shown that certain retinoids sensitize some cancer cells to TRAIL-induced apoptosis by upregulating either TRAIL or the TRAIL receptors DR4 and DR5 (also known as TNFRSF10A and TNFRSF10B, respectively) 9, 10 . To test the effect of RAc on normal cells in our setting, we examined the expression of TRAIL receptors in NCM356, BW1779 and CRL1831 (another immortalized normal human colon epithelial cell line) cells after RAc treatment. Although RAc did not induce TRAIL expression (data not shown), it induced DR4 or DR5 expression in these cells ( Fig. 2d and Supplementary Fig. 6a) . Notably, RAc strongly suppressed DcR1 (also known as TNFRSF10C) expression in these cells (Fig. 2d and Supplementary Fig. 6a ). In addition, DcR2 (TNFRSF10D) expression was inhibited by RAc in NCM356 cells (Fig. 2d) . We further showed that RAc caused similar changes in messenger RNA levels in NCM356 cells ( Supplementary Fig. 6b ), suggesting that RAc modulates TRAIL receptor expression at the levels of mRNA.
Overexpression of DR5 sensitized APC-knockdown cells to TRAIL-induced caspase 8 cleavage and activation ( Fig. 2e and Supplementary Fig. 6c ). Pretreatment of APC-knockdown cells with a DcR1-neutralizing antibody to block the TRAIL-DcR1 interaction also partially induced caspase 8 cleavage and activation after TRAIL treatment, and this effect was further enhanced in DR5-transfected cells ( Fig. 2e and Supplementary Fig. 6c ). Similar results were obtained in BW1799 cells ( Supplementary Fig. 6d , e). These data indicate that both induction of DR5 and suppression of DcR1 contribute to the effect of RAc in sensitizing APC-deficient cells to apoptosis. We
Min mice with TRAIL and lowdose RAc for 15 treatment cycles over 6 weeks. We observed that TRAIL and RAc significantly inhibited the growth of intestinal polyps as compared to controls (Fig. 3a) . Histological analysis of tumours and adjacent normal tissues in treated mice showed that many cells in tumours, but not in normal tissues, contain condensed nuclei, suggesting that cells in the tumours are dying (Fig. 3b) . This observation was confirmed by TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling) analysis (Fig. 3b) . When the total numbers and sizes of the polyps were compared 1 month after the 6-week treatment period, the treated mice showed on average a fourto fivefold decrease in the total number of polyps relative to the mice treated with PBS control (Fig. 3c) . The reduction in large polyps ($2 mm) was much more pronounced (to about 1/30 of control) (Fig. 3c ). These data demonstrate that the combination of TRAIL and RAc induces apoptosis specifically in Apc-defective polyps and effectively suppresses the tumour growth.
Biochemically, the accumulation of soluble b-catenin and induction of c-Myc expression were seen in the polyps of Apc Min mice but not in normal tissue (Supplementary Fig. 7a ). c-FLIP protein was readily detectable in normal tissue, whereas it was significantly reduced in polyps (Supplementary Fig. 7a ). Consistent with our in vitro observations, RAc induced DR5 expression and repressed DcR1 in both the polyps in Apc Min mice (Supplementary Fig. 7b ). Because TRAIL and RAc together target APC-deficient cells for apoptosis, this combination has the potential to achieve chemoprevention in short-term therapy. To test this, we applied two short consecutive TRAIL and RAc treatment cycles to Apc Min within a week and analysed the intestinal tumours 2 weeks after treatment. After only two treatments, we observed a 69% reduction in the number of polyps when 3 mg kg 21 TRAIL and 68 mg kg 21 RAc were injected into Apc Min mice (Fig. 3d) . The tumour numbers were further reduced to 10% of the control when tenfold higher doses of TRAIL and RAc were used (Fig. 3d) . These data indicate that short-term treatment with TRAIL and RAc is capable of inhibiting growth of premalignant cells in Apc Min mice. To test the effect of TRAIL and RAc treatment on the survival of Apc Min mice, we applied five non-consecutive TRAIL and RAc treatments to Apc Min mice within 4 months (average 1 treatment every 3 weeks). All mice in the control group treated with PBS died within 7 months; however, five of the seven treated mice survived beyond 8 months (P # 0.001) (Fig. 3e) , demonstrating that noncontinuous TRAIL and RAc treatment yields a long-term survival benefit for Apc Min mice. Although it is likely that the two early deaths in the treatment group resulted from a late start in treatment, it cannot be ruled out that intrinsic resistance, heterogeneity, genetic or epigenetic changes of premalignant cells can influence the effect of TRAIL treatment. Further study will provide a more in-depth assessment.
As a first step to demonstrating the efficacy and relevance of TRAIL and RAc treatment in humans, we treated biopsy samples of both normal and tumour regions from consenting familial adenomatous polyposis (FAP) patients under organ culture conditions as reported 17, 18 . A cross-section of normal colon tissue showed a round and defined structure of individual villus consisting of a monolayer of colon epithelial cells and membrane b-catenin staining pattern, whereas dysplastic colon polyps showed much larger villi, bigger nuclei, an irregular structure consisting of several epithelial layers, and enhanced nuclear b-catenin staining (Fig. 4a) . Treatment of normal tissue slices with TRAIL and RAc did not induce significant cell death, whereas the same treatment in the polyp samples resulted in significant cell death, as detected by TUNEL assay (Fig. 4a) . Quantification of TUNEL-positive cells showed that TRAIL and RAc killed an average of 57% of the cells in the human colon polyps (Fig. 4b) . These results verify that TRAIL and RAc are effective against human polyps from FAP patients in vitro, and that our approach holds promise for the chemoprevention of colon cancer in humans.
A major concern in chemoprevention is potential toxicity associated with treatment. We have shown that TRAIL and RAc target the APC-b-catenin-c-Myc signalling pathway for apoptosis. Because activation of b-catenin is involved in stem cell self-renewal and maintenance in adult tissues 19 , TRAIL and RAc could possibly interact in a detrimental way with stem cells. To investigate this, we first tested the effect of TRAIL and RAc on intestinal stem cells (ISCs) in Apc Min mice. Using the putative ISC marker leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5) 20 , we noted that most of the Lgr5-positive cells in the normal sections were located at the bottom of the crypt as reported 20 (Fig. 4c) . Staining of active caspase 3 showed extensive staining in tumour sections, similar to the findings shown in Fig. 3b (Fig. 4c) . More importantly, no staining was detected in serial sections from the normal region, including Lgr5 1 cells in the crypt regions where the ISC resides (Fig. 4c) . We also studied the effect of long-term TRAIL and RAc treatment on tissue-resident stem cells isolated from pararenal adipose tissue (mice adipose-tissuederived stem cells, or mASCs) of Apc Min mice 21 ( Supplementary  Fig. 8 ). We found no detectable effect on morphology (data not shown), neural differentiation (data not shown), proliferation and apoptosis, senescence, osteogenesis and adipogenesis both in vitro and in vivo (Supplementary Figs 9 and 10) . Taken together, these results indicate that TRAIL and RAc exert no negative effect on stem cells (ISCs and mASCs) in mice.
In summary, we discovered a synergistic interaction among TRAIL, RAc and tumour suppressor APC, which results in the specific induction of apoptosis in APC-deficient cells by TRAIL and RAc ( Supplementary Fig. 11 ). Induction of apoptosis represents a most potent cellular mechanism against cancer, and selectively eliminating premalignant tumour cells by TRAIL and RAc is an effective method of chemoprevention. More notably, we demonstrate that the chemopreventive effect of TRAIL and RAc can be achieved by short-term intermittent and non-continuous treatment cycles. Thereby, the potential side effects and costs often associated with long-term treatment could be minimized and controlled.
METHODS SUMMARY
Recombinant soluble human TRAIL was prepared according to a published method 22 . For TRAIL and RAc treatment, the cells were first treated with RAc (6.8 ng ml
21
) for 48 h, and then TRAIL (50 or 500 ng ml 21 ) was added. Cell viability was determined using the Annexin V-FITC Apoptosis Detection Kit (Sigma). Caspase 3/7 activity was measured using the Apo-ONE Homogeneous Caspase 3/7 assay kit (Promega). Transfection and western blotting were performed as described previously 23 . The apoptotic cells in tumour samples were detected by TUNEL assay using an apoptosis detection kit (R&D Systems) or by caspase 3 staining using an anti-cleaved caspase 3 antibody (Cell Signaling). Apc Min mice were purchased from the Jackson Laboratory. For treatment, Apc Min mice at 3 months of age were first given RAc by intraperitoneal (i.p.) injection at 68 mg kg
. After 48 h, an i.p. injection of TRAIL was given at 3 mg kg 21 . After 24 h, RAc was injected again, followed by TRAIL injection. The procedure was repeated for 6 weeks, resulting in a total of 15 treatment cycles. Whole intestines were collected immediately after euthanasia and opened longitudinally so that polyps could be counted and measured. Min mice were treated with five non-continuous cycles of TRAIL and RAc. Both the normal tissue and polyps of the intestine were serially sectioned and stained with Lgr5 (brown), activated caspase 3 (red), or both. Many serial sections were analysed and representative photographs are shown. Original magnification, 360.
